Bavarian Nordic AS BAVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 245.00
- Day Range
- DKK 241.80–247.40
- 52-Week Range
- DKK 171.30–247.40
- Bid/Ask
- DKK 247.00 / DKK 247.40
- Shares Outstanding
- 75.05M
- Market Cap
- DKK 18.57B
- Volume/Avg
- 234,822 / 190,950
Key Statistics
- Price/Earnings (Normalized)
- 12.68
- Price/Sales
- 3.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 2.41%
Company Profile
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,861
- Website
- https://www.bavarian-nordic.com
Valuation
|
Metric
|
BAVA
|
|---|---|
Price/Earnings (Normalized) | 12.68 |
Price/Book Value | 1.42 |
Price/Sales | 3.10 |
Price/Cash Flow | 7.23 |
Price/Earnings
BAVA
Financial Strength
|
Metric
|
BAVA
|
|---|---|
Quick Ratio | 3.83 |
Current Ratio | 6.53 |
Interest Coverage | 229.29 |
Quick Ratio
BAVA
Profitability
|
Metric
|
BAVA
|
|---|---|
Return on Assets (Normalized) | 10.98% |
Return on Equity (Normalized) | 12.55% |
Return on Invested Capital (Normalized) | 12.21% |
Return on Assets
BAVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^@<#?f? | LOCK|Qy?Q$ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|XVJS&K | LOCK|FZ@X | $83B | |||
| Moderna Inc
MRNA
| LOCK|^^X@^Dh | LOCK|jX | $80B | |||
| argenx SE ADR
ARGX
| LOCK|!&$@xN | LOCK|h?% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bynXB@ | LOCK|r> | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d@&^>> | LOCK|!ZFl | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<!DdPf^z | LOCK|QJ@Y? | $28B | |||
| Incyte Corp
INCY
| LOCK|<H<#sTd | LOCK|#>$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&$^w$#Q | LOCK|%> | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^K$!?x | LOCK|C@q | $14B |
United States